EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics

Natalia A Quijano Cardé, Jin Niu, Yue Guo, Jia Zhou, Xiao Qiu, Yaming Su, Carlos Pérez-Ruixo, Deeksha Vishwamitra, Caroline Hodin, Tara Stephenson, Athena Zuppa, Katherine Chastain und 7 weitere

Targeted Oncology · 2026-05 · 21 (3) · 373-383

DOI: 10.1007/s11523-026-01205-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, online erschienen am 26.03.2026. Verfasst von Natalia A Quijano Cardé und 18 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Spring House, PA, USA. nquijano@its.jnj.com. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Cytokines, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCytokinesMultiple MyelomaFemaleHumansMaleRetrospective StudiesClinical Trials, Phase I as TopicClinical Trials, Phase II as Topic

Substanzen

Antibodies, BispecificCytokines

Autor:innen und Institutionen

  • Johnson & Johnson, Spring House, PA, USA. nquijano@its.jnj.com.
  • Johnson & Johnson, Spring House, PA, USA.
  • Johnson & Johnson, Raritan, NJ, USA.
  • Johnson & Johnson, Madrid, Spain.
  • Johnson & Johnson, Beerse, Antwerp, Belgium.
  • Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Förderung

  • Johnson & Johnson

Zitieren

APA

Cardé, N. A. Q., Niu, J., Guo, Y., Zhou, J., Qiu, X., Su, Y., Pérez-Ruixo, C., Vishwamitra, D., Hodin, C., Stephenson, T., Zuppa, A., Chastain, K., Kobos, R., Samtani, M. N., Wang, W., Haddish-Berhane, N., Van de Donk, N. W. C. J., Garfall, A. L., & Matous, J. V. (2026). Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics. Targeted Oncology, 21(3), 373-383. https://doi.org/10.1007/s11523-026-01205-4

Vancouver

Cardé NAQ, Niu J, Guo Y, Zhou J, Qiu X, Su Y, et al. Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics. Targeted Oncology. 2026;21(3):373-383. doi:10.1007/s11523-026-01205-4

BibTeX
@article{Card2026,
  author = {Cardé, Natalia A Quijano and Niu, Jin and Guo, Yue and Zhou, Jia and Qiu, Xiao and Su, Yaming and Pérez-Ruixo, Carlos and Vishwamitra, Deeksha and Hodin, Caroline and Stephenson, Tara and Zuppa, Athena and Chastain, Katherine and Kobos, Rachel and Samtani, Mahesh N and Wang, Weirong and Haddish-Berhane, Nahor and Van de Donk, Niels W C J and Garfall, Alfred L and Matous, Jeffrey V},
  title = {Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics},
  journal = {Targeted Oncology},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {373--383},
  doi = {10.1007/s11523-026-01205-4}
}
Kostenlos starten →